Clinical Trial

Study to Investigate the Efficacy of Abrocitinib in Adult Participants With Severe Fatigue From Post COVID Condition/Long COVID

Study acronym: CLEAR-LC
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The primary purpose of this phase 2a study is to compare the efficacy of abrocitinib to placebo in improving severe fatigue in non-hospitalized adults with symptomatic Post-COVID Condition (PCC) (also called Long COVID). We are also interested in learning if abrocitinib is effective in improving overall health status in people suffering from severe fatigue from PCC. Eligible participants with a confirmed history of COVID19 infection who also have PCC according to the World Health Organization definition, will be randomized to receive abrocitinib at a dose of 50 mg, 100 mg, or placebo by mouth daily for 12 weeks (84 days).
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2024-09-12; most recent amendment 2026-04-16.
Status change: Recruiting → Active, Not Recruiting 2025-12-12
Status change: Not Yet Recruiting → Recruiting 2024-12-16
Trial Details
NCT Number NCT06597396
Lead Sponsor Beth Israel Deaconess Medical Center
Collaborators: Pfizer
Conditions Post-COVID Condition, Fatigue Symptom
Enrollment 46 participants
Start Date 2024-12-27
Primary Completion 2026-03-27 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-20